Neurologia i neurochirurgia polska最新文献

{"title":"Advances in CSF1R-related disorder: novel mutations, dopaminergic imaging, and overcoming underdiagnosis.","authors":"Jarosław Dulski","doi":"10.5603/pjnns.113165","DOIUrl":"https://doi.org/10.5603/pjnns.113165","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":"60 3","pages":"243-245"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut and skin microbiome profiles as promising biomarkers in Parkinson's disease - preliminary results.","authors":"Anna Jakubczyk-Słabicka, Jakub Kasprzak, Karolina Skonieczna-Żydecka, Jarosław Sławek, Magdalena Górska-Ponikowska","doi":"10.5603/pjnns.108273","DOIUrl":"10.5603/pjnns.108273","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"114-116"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood-brain barrier-associated serum proteins in epilepsy - clinical and diagnostic implications.","authors":"Elżbieta Bronisz, Agnieszka Cudna, Aleksandra Wierzbicka, Iwona Kurkowska-Jastrzębska","doi":"10.5603/pjnns.109090","DOIUrl":"10.5603/pjnns.109090","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"119-120"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olfaction, cognition, and educational level in Parkinson's disease - perspectives from a Brazilian cohort.","authors":"Josevania Fulgencio de Lima Arruda","doi":"10.5603/pjnns.111495","DOIUrl":"10.5603/pjnns.111495","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"497-498"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and feasibility of Ommaya reservoir for intrathecal chemotherapy in patients with leptomeningeal disease.","authors":"Ehab Harahsheh, Shiv Shah, Richard J Butterfield, Carl C Ariete, Eric J Yancey, Jenna H Meyer, Mark K Lyons, Chandan Krishna, Shannon Fortin-Ensign, Richard S Zimmerman, Bernard R Bendok, Maciej M Mrugala","doi":"10.5603/pjnns.105907","DOIUrl":"10.5603/pjnns.105907","url":null,"abstract":"<p><strong>Aim of the study: </strong>To assess safety and feasibility of intrathecal chemotherapy (IC) and disease monitoring via Ommaya reservoir (OR) in routine clinical practice in patients with leptomeningeal disease (LMD).</p><p><strong>Clinical rationale of the study: </strong>Leptomeningeal disease carries poor prognosis with an average survival of 3-6 months after diagnosis. OR are an accessible alternative to serial lumbar punctures for delivery of IC and disease monitoring in these patients but are not widely used, partially due to safety concerns.</p><p><strong>Material and methods: </strong>This single-center retrospective cohort study enrolled patients who received at least one administration of IC via OR for LMD between 2017 and 2022 at a tertiary academic center. Demographics, primary malignancy, treatment type, complications, adverse events and outcomes were recorded for each enrolled patient.</p><p><strong>Results: </strong>We identified 22 patients (17 females, 5 males) with mean age 50.9 ± 14.8 years. The primary cancers were breast (12), leukemia (3), ovarian carcinoma (3), CNS lymphoma (1), urothelial carcinoma (1), spinal melanocytoma (1), and high-grade glioma (1). A total of 208 IC injections via OR were performed [median 9 OR injections per patient (interquartile range (IQR) 5-13)]. Five patients (23%) experienced mild adverse events of grade 2 or lower by Common Terminology Criteria for Adverse Events. The overall risk of adverse events from injections was 3.4% (7/208). Eight patients (36.3%) converted into negative CSF cytology and 18 patients (82%) had clinical and/or radiological progression of their LMD (median 2 months following first injection). Eleven patients (50%) died of their LMD during follow-up. Median OS and PFS from the first injection were 5.3 months [95% CI: 4.8-NE (not estimable)] and 4.3 months [95% CI: 1.8-16.0], respectively.</p><p><strong>Conclusions and clinical implications: </strong>Our single-center cohort study suggests that the use of intrathecal chemotherapy via Ommaya reservoir in routine clinical practice is a safe and feasible option and should be considered for treatment and frequent disease monitoring in eligible patients with leptomeningeal disease. Neurologists, especially neuro-oncologists, can significantly contribute to the care of patients of leptomeningeal disease via administering intrathecal chemotherapy.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"75-82"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairment in cervical dystonia: core clinical feature or secondary effect related to non-motor symptoms?","authors":"Małgorzata Dudzic, Anna Pieczyńska, Artur Drużdż, Anna Rajewska, Piotr Dudzic, Katarzyna Hojan","doi":"10.5603/pjnns.108986","DOIUrl":"10.5603/pjnns.108986","url":null,"abstract":"<p><strong>Aim of the study: </strong>To investigate subtle cognitive dysfunction in patients with cervical dystonia (CD) as a potential independent non-motor feature of the disease or as a consequence of interactions between motor and other non-motor symptoms (NMS).</p><p><strong>Clinical rationale for the study: </strong>Cognitive impairment represents one of the most common non-motor symptoms in patients with cervical dystonia. However, the interrelations between cognitive dysfunction, motor symptoms, and other non-motor symptoms remain insufficiently explored.</p><p><strong>Material and methods: </strong>Patients with CD (n = 34) underwent comprehensive assessment at baseline and 4-6 weeks after botulinum toxin (BoNT) treatment. Clinical and sociodemographic variables, as well as motor and non-motor symptoms of dystonia were assessed. Matched controls (n = 33) underwent a single assessment. Cognitive function, depressive and anxiety symptoms, and sleep disturbances were assessed by a neuropsychologist in both groups.</p><p><strong>Results: </strong>At baseline, 52.9% of patients with CD scored below the Montreal Cognitive Assessment (MoCA) cut-off for cognitive impairment, compared with 3.0% of healthy controls. Patients also showed higher rates of depressive symptoms, anxiety, and sleep disturbances. Cognitive performance was significantly lower in the CD group across multiple domains [executive functions, visuospatial abilities, language, memory, and attention (p < 0.05)]. Following botulinum toxin treatment, significant improvements were observed in overall MoCA scores and in specific domains of executive function, visuospatial abilities, language, and memory (p < 0.05). No correlation was found between overall dystonia severity and cognitive performance, although executive function correlated with motor symptom severity at baseline (R = -0.41, p = 0.017). In the multivariate model, sleep disturbances were identified as the strongest negative predictor of cognitive function (β = -0.40, p = 0.006), while higher education showed a protective effect. Other variables, including depression, anxiety, age, disease duration, and dystonia severity, were not significant predictors.</p><p><strong>Conclusions and clinical implications: </strong>The study explores cognitive impairment in cervical dystonia in relation to motor severity and non-motor domains, with the multivariable model suggesting a potential role of sleep disturbances. The findings do not allow a definitive distinction between cognitive impairment as a core feature of dystonia or a secondary effect related to non-motor symptoms, but they indicate complex and interdependent mechanisms.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"320-328"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147355893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glymphatic function in functional movement disorders: expanding the search for biomarkers.","authors":"Monika Figura, Kamila Kopeć, Stanisław Szlufik, Dariusz Koziorowski","doi":"10.5603/pjnns.112368","DOIUrl":"10.5603/pjnns.112368","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"250-251"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss of therapeutic efficacy following the switch from levodopa/carbidopa intestinal gel therapy to subcutaneous foslevodopa/foscarbidopa infusion in a patient with advanced Parkinson's disease.","authors":"Anna Roszmann, Radosław Piekarski, Przemysław Mongird-Niklewski, Jarosław Sławek","doi":"10.5603/pjnns.108714","DOIUrl":"10.5603/pjnns.108714","url":null,"abstract":"","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"111-113"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive versus continuous invasive blood pressure monitoring during endovascular treatment of acute ischemic stroke under general anesthesia - a pilot study.","authors":"Marcin Wiącek, Katarzyna Koszarska, Aleksandra Kotlińska, Katarzyna Wąchała, Sylwia Lepak, Katarzyna Jucha, Halina Bartosik-Psujek","doi":"10.5603/pjnns.107681","DOIUrl":"10.5603/pjnns.107681","url":null,"abstract":"<p><strong>Aim of the study: </strong>To assess the agreement between continuous invasive (IBP) and intermittent non-invasive blood pressure (NIBP) monitoring during endovascular treatment (EVT) of acute ischemic stroke (AIS) under general anesthesia, and to evaluate the frequency of clinically relevant discrepancies between both methods and the potential impact of IBP use on treatment initiation times.</p><p><strong>Clinical rationale for the study: </strong>Intraprocedural hypotension during mechanical thrombectomy (MT) is associated with worse outcomes in AIS patients. While continuous IBP monitoring is frequently used during procedures with high-risk of hypotension, it is not universally adopted in stroke EVT. Accurate, real-time hemodynamic monitoring may be essential to guide timely therapeutic interventions and optimize outcomes.</p><p><strong>Materials and methods: </strong>In this prospective observational study, 30 AIS patients undergoing MT under general anesthesia were included. Simultaneous IBP and NIBP measurements were recorded throughout the procedure. Non-invasive blood pressure was measured every 5 minutes on one arm, while IBP was continuously recorded from a radial arterial catheter in the contralateral upper extremity. Paired readings were analyzed using Bland-Altman plots. The proportion of time with clinically relevant discrepancies between measurements was calculated. Additionally, door-to-groin (DTG) times were compared between patients with and without intended IBP monitoring.</p><p><strong>Results: </strong>A total of 481 paired IBP and NIBP readings were analyzed. While mean differences for systolic blood pressure (SBP) and mean arterial pressure (MAP) were small (-0.64 mm Hg and -0.99 mm Hg, respectively), limits of agreement were wide (SBP: -40.6 to 39.4 mm Hg; MAP: -28.5 to 26.5 mm Hg). Diastolic blood pressure (DBP) showed poor agreement with a mean bias of -7.64 mm Hg. Discrepancies of ≥ 20 mm Hg for SBP occurred in 41.0% (IQR = 28.0-59.4%) of the procedure time, and discrepancies > 15 mm Hg for MAP in 29.6% (IQR = 22.8-58.5%). DTG times did not differ significantly between the IBP and NIBP groups (median: 41 vs. 38 minutes, p = 0.217).</p><p><strong>Conclusions and clinical implications: </strong>Non-invasive blood pressure may show limited agreement with IBP and miss clinically relevant hemodynamic changes due to its intermittent nature and overestimation of blood pressure during hypotensive episodes. Invasive monitoring does not appear to delay treatment initiation and may improve blood pressure control in AIS patients undergoing EVT under general anesthesia. These findings, from a pilot study, should be interpreted with caution but provide a basis for larger prospective investigations.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"51-59"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alzheimer's disease: a clinical update on diagnosis and treatment.","authors":"Dror Shir, Christian Lachner","doi":"10.5603/pjnns.109190","DOIUrl":"10.5603/pjnns.109190","url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's disease (AD) is the leading cause of dementia, characterized by progressive cognitive and functional decline. As the population ages, the prevalence of AD is expected to increase significantly, imposing a growing burden on patients, caregivers, and healthcare systems. Advances in our understanding of AD pathophysiology and biomarker-based diagnosis have redefined clinical practice, introducing challenges in early detection, accurate diagnosis, and effective treatment.</p><p><strong>State of the art: </strong>Current AD diagnostic frameworks incorporate clinical assessment alongside biomarkers of amyloid and tau pathology, cerebrovascular contributions, and neurodegeneration. Imaging modalities and fluid biomarker analyses enable more precise diagnosis, although accessibility remains limited in many settings. Recent therapeutic advancements in the form of anti-amyloid monoclonal antibodies offer disease-modifying potential but are accompanied by implementation challenges, such as patient selection, monitoring for adverse events, and cost considerations.</p><p><strong>Clinical implications: </strong>Integrating biomarker testing into routine clinical practice requires a careful review of individual risks and benefits for each patient, balancing diagnostic accuracy with practical considerations like testing consequences, test availability, pretest probability, and patient preferences. Shared decision-making is pivotal when discussing treatment options, weighing potential clinical benefits against risks and the overall burden of care.</p><p><strong>Future directions: </strong>Enhancing the delivery of anti-amyloid antibodies and advancing research into tau-targeted therapies represent promising therapeutic avenues. Incorporating scalable, non-invasive biomarkers, e.g., plasma-based biomarkers, into clinical practice has the potential to transform diagnostic workflows, provided they are applied in appropriate clinical contexts. Bridging the gap between research innovations and real-world implementation will require coordinated, multidisciplinary collaboration across healthcare systems.</p>","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"128-137"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}